Roivant Sciences Ltd.NASDAQ: ROIV

Priovant Announces Positive Phase 2 Results for Brepocitinib in Cutaneous Sarcoidosis (CS)

· Issued by Roivant Sciences Ltd.
Watch Roivant Sciences explain itRoivant Sciences Ltd. (ROIV) Q1 2026 Earnings Call · Replay · Aug 6
  • Brepocitinib 45 mg significantly improved cutaneous sarcoidosis disease activity, achieving a 22.3-point improvement in mean CSAMI-A at Week 16 versus a 0.7-point improvement in placebo (Δ 21.6 P